Recital 17, Regulation (EU) 2025/117

In forcesince 24 Jan 2025

Where joint scientific consultations on medical devices are conducted in parallel with the expert panel consultation, the HTA secretariat and the European Medicines Agency should exchange the respective lists of issues. The JSC Subgroup and the expert panel should discuss the lists of issues with the health technology developer in one single meeting. It should be specified which parties are to be invited to this joint meeting. The meeting should be held virtually and be co-chaired by the assessor or co-assessor for joint scientific consultation and one of the rapporteurs for the expert panel consultation.